Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used As Diagnostic or Theranostic Biomarkers?

Overview

Journal Noncoding RNA

Date 2020 Aug 28

PMID 32846922

Citations 3

Authors

Andrew Gibbons

Suresh Sundram

Brian Dean

Affiliations

Soon will be listed here.

Abstract

The similarities between the depressive symptoms of Major Depressive Disorders (MDD) and Bipolar Disorders (BD) suggest these disorders have some commonality in their molecular pathophysiologies, which is not apparent from the risk genes shared between MDD and BD. This is significant, given the growing literature suggesting that changes in non-coding RNA may be important in both MDD and BD, because they are causing dysfunctions in the control of biochemical pathways that are affected in both disorders. Therefore, understanding the changes in non-coding RNA in MDD and BD will lead to a better understanding of how and why these disorders develop. Furthermore, as a significant number of individuals suffering with MDD and BD do not respond to medication, identifying non-coding RNA that are altered by the drugs used to treat these disorders offer the potential to identify biomarkers that could predict medication response. Such biomarkers offer the potential to quickly identify patients who are unlikely to respond to traditional medications so clinicians can refocus treatment strategies to ensure more effective outcomes for the patient. This review will focus on the evidence supporting the involvement of non-coding RNA in MDD and BD and their potential use as biomarkers for treatment response.

Citing Articles

Deciphering the epigenetic role of long non-coding RNAs in mood disorders: Focus on human brain studies.

Roy B, Verma A, Funahashi Y, Dwivedi Y Clin Transl Med. 2025; 15(3):e70135.

PMID: 40038891 PMC: 11879898. DOI: 10.1002/ctm2.70135.

Differential Expression of tRNA-Derived Small RNA Markers of Antidepressant Response and Functional Forecast of Duloxetine in MDD Patients.

Wang X, Gao M, Song J, Li M, Chen Y, Lv Y Genes (Basel). 2025; 16(2).

PMID: 40004491 PMC: 11855652. DOI: 10.3390/genes16020162.

Autism spectrum disorder: difficulties in diagnosis and microRNA biomarkers.

Martinez B, Peplow P Neural Regen Res. 2024; 20(10):2776-2786.

PMID: 39314171 PMC: 11826456. DOI: 10.4103/NRR.NRR-D-24-00712.

Association between Mir-17-92 gene promoter polymorphisms and depression in a Chinese population.

Liang P, Yang X, Long R, Li Y, Wang Z, Yang P BMC Med Genomics. 2024; 17(1):123.

PMID: 38711022 PMC: 11075371. DOI: 10.1186/s12920-024-01894-8.

MiR-15b-5p Expression in the Peripheral Blood: A Potential Diagnostic Biomarker of Autism Spectrum Disorder.

Hosokawa R, Yoshino Y, Funahashi Y, Horiuchi F, Iga J, Ueno S Brain Sci. 2023; 13(1).

PMID: 36672009 PMC: 9855964. DOI: 10.3390/brainsci13010027.

References

Roy B, Dunbar M, Shelton R, Dwivedi Y . Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder. Neuropsychopharmacology. 2016; 42(4):864-875. PMC: 5312059. DOI: 10.1038/npp.2016.175. View

McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A . The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003; 60(5):497-502. DOI: 10.1001/archpsyc.60.5.497. View

McGuffin P, Katz R . The genetics of depression and manic-depressive disorder. Br J Psychiatry. 1989; 155:294-304. DOI: 10.1192/bjp.155.3.294. View

Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E . Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ. 2006; 334(7587):242. PMC: 1790752. DOI: 10.1136/bmj.39041.445104.BE. View

Fries G, Lima C, Valvassori S, Zunta-Soares G, Soares J, Quevedo J . Preliminary investigation of peripheral extracellular vesicles' microRNAs in bipolar disorder. J Affect Disord. 2019; 255:10-14. DOI: 10.1016/j.jad.2019.05.020. View

Doherty J, Owen M . Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice. Genome Med. 2014; 6(4):29. PMC: 4062063. DOI: 10.1186/gm546. View

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

Bangemann K, Schulz W, Wohlleben J, Weyergraf A, Snitjer I, Werfel T . [Depression and anxiety disorders among psoriasis patients: protective and exacerbating factors]. Hautarzt. 2014; 65(12):1056-61. DOI: 10.1007/s00105-014-3513-9. View

Huang L, Jiang X, Li Z, Li J, Lin X, Hu Z . Linc00473 potentiates cholangiocarcinoma progression by modulation of DDX5 expression via miR-506 regulation. Cancer Cell Int. 2020; 20:324. PMC: 7368746. DOI: 10.1186/s12935-020-01415-4. View

10.

Sayad A, Taheri M, Omrani M, Fallah H, Kholghi Oskooei V, Ghafouri-Fard S . Peripheral expression of long non-coding RNAs in bipolar patients. J Affect Disord. 2019; 249:169-174. DOI: 10.1016/j.jad.2019.02.034. View

11.

Sawyer I, Dundr M . Chromatin loops and causality loops: the influence of RNA upon spatial nuclear architecture. Chromosoma. 2017; 126(5):541-557. DOI: 10.1007/s00412-017-0632-y. View

12.

Lopez J, Kos A, Turecki G . Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response. Curr Opin Psychiatry. 2017; 31(1):7-16. DOI: 10.1097/YCO.0000000000000379. View

13.

Williamson V, Mamdani M, McMichael G, Kim A, Lee D, Bacanu S . Expression quantitative trait loci (eQTLs) in microRNA genes are enriched for schizophrenia and bipolar disorder association signals. Psychol Med. 2015; 45(12):2557-69. PMC: 4845662. DOI: 10.1017/S0033291715000483. View

14.

Rapoport S . Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci. 2014; 5(6):459-67. PMC: 4063504. DOI: 10.1021/cn500058v. View

15.

Amoah S, Rodriguez B, Logothetis C, Chander P, Sellgren C, Weick J . Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics. Neuropsychopharmacology. 2019; 45(4):656-665. PMC: 7021900. DOI: 10.1038/s41386-019-0579-1. View

16.

Mompeon A, Ortega-Paz L, Vidal-Gomez X, Costa T, Perez-Cremades D, Garcia-Blas S . Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis. Sci Rep. 2020; 10(1):5373. PMC: 7096393. DOI: 10.1038/s41598-020-61507-z. View

17.

John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D . Human MicroRNA targets. PLoS Biol. 2004; 2(11):e363. PMC: 521178. DOI: 10.1371/journal.pbio.0020363. View

18.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

19.

van den Berg M, Krauskopf J, Ramaekers J, Kleinjans J, Prickaerts J, Briede J . Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Prog Neurobiol. 2019; 185:101732. DOI: 10.1016/j.pneurobio.2019.101732. View

20.

Burenina O, Oretskaya T, Kubareva E . Non-Coding RNAs As Transcriptional Regulators In Eukaryotes. Acta Naturae. 2018; 9(4):13-25. PMC: 5762824. View